Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 30 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 8390
Sealed predictions
- VRK3 in dopamine neurons, braak-0.08 (p 0.832) → -0.11 (p 0.775)receipt 8398
Swarm cases
receipt 8398: VRK3 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.188, n 18), 95% CI -0.69 to +0.17. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.31 (p 0.204, n 18). could be the mix.
- skeptic
- leave-one-out range -0.46 to -0.23, sign flips 0; without severely affected donors -0.33 (p 0.188, n 18). fragile.
- cell type
- strongest in astrocytes: -0.73 (p 5.6e-4, n 18) vs -0.33 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VRK3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up VRK3 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.28 p 0.328 (needs p < 2.5e-4)
Receipts
loading the receipts